<p>In a report on 22nd of January 2019 <a href="https://en.wikipedia.org/wiki/Glenmark_Pharmaceuticals">Glenmark Pharmaceuticals</a> said that it has received an USFDA approval for Derma-Smoothe topical oil a generic version drug used for the treatment of Scalp psoriasis.</p><p>Glenmark Pharmaceuticals Inc, USA (Glenmark) has been granted final approval by the United States Food &amp;amp; Drug Administration (USFDA) for Fluocinolone Acetonide Topical Oil, 0.01 per cent (scalp oil), a generic version of Derma-Smoothe/FS Topical Oil, 0.01 per cent (scalp oil), of Hill Dermaceuticals, Inc,&amp;quot; the company said in a BSE filing.</p><blockquote><p>For the 12 months to September 2018, Derma Smoothe/FS Topical Oil, 0.01 per cent (scalp oil), achieved annual sales of around USD 14 million, Glenmark said, citing IQVIA sales data.</p></blockquote><p>For the 12 months to September 2018, Derma Smoothe/FS Topical Oil, 0.01 per cent (scalp oil), achieved annual sales of around USD 14 million, Glenmark said, citing IQVIA sales data.</p><p>The company&#039;s current portfolio consists of 141 products authorised for distribution at the US marketplace and 58 Abbreviated New Drug Applications (ANDAs) pending approval with the USFDA.</p><p>Story source/Credit : IST</p>